3rd Quarter - Report — PROFESSIONAL COMPOUNDING CENTERS OF AME… for PROFESSIONAL COMPOUNDING CENTERS OF AME… (2015)

Firm

PROFESSIONAL COMPOUNDING CENTERS OF AMERICA

Client

PROFESSIONAL COMPOUNDING CENTERS OF AMERICA

Income

—

Expenses

$150,000

Expense method

A: Lobbying Disclosure Act definitions

What was lobbied

4 issue areas, each in the filer's own words, with who lobbied on it and where.

Pharmacy PHA

Issues related to FDA implementation of The Drug Quality and Security Act; Issues related to constructive transfer and the Ensuring Safe Access to Prescription Medication Act of 2014; issues related to animal drug compounding; Saving Access to Compounded Medications for Special Needs Patients Act (S/1406).

Lobbyist	Covered position, as disclosed
AARON RAFAEL LOPEZ	—
AMY SHANK	—

Contacted: Defense, Dept of (DOD); HOUSE OF REPRESENTATIVES; Food & Drug Administration (FDA); SENATE

Health Issues HCR

TriCare benefit issues.

Lobbyist	Covered position, as disclosed
AARON RAFAEL LOPEZ	—
AMY SHANK	—

Contacted: SENATE; Food & Drug Administration (FDA); Defense, Dept of (DOD); HOUSE OF REPRESENTATIVES

Medicare/Medicaid MMM

Issues related to Medicare coverage of compounded medications.

Lobbyist	Covered position, as disclosed
AARON RAFAEL LOPEZ	—
AMY SHANK	—

Contacted: Food & Drug Administration (FDA); SENATE; HOUSE OF REPRESENTATIVES; Defense, Dept of (DOD)

Budget/Appropriations BUD

Agricultural Appropriations Spending Bill, specifically FDA funding for implementation of the Drug Quality and Security Act.

Lobbyist	Covered position, as disclosed
AARON RAFAEL LOPEZ	—
AMY SHANK	—

Contacted: Food & Drug Administration (FDA); Defense, Dept of (DOD); HOUSE OF REPRESENTATIVES; SENATE

Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.